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Experimental autoimmune encephalomyelitis (EAE) is a T lymphocyte-mediated autoimmune 
disease of the CNS. Significant roles for B cells and a rare IL-10-producing CD1dhiCD5+ 
regulatory B cell subset (B10 cells) have been identified during the initiation and progression of 
EAE. Whether and how the regulatory functions of B10 cells and regulatory FoxP3+ T cells 
(Treg) overlap or influence EAE immunopathogenesis independently has remained unanswered. 
The current studies demonstrate that the number of endogenous or adoptively transferred B10 
cells directly influenced EAE pathogenesis through their production of IL-10. B10 cell numbers 
expanded quickly within the spleen but not CNS following myelin oligodendrocyte glycoprotein 
(MOG35-55) immunization, which paralleled B10 cell regulation of disease initiation. The 
adoptive transfer of MOG33-35-sensitized B10 cells into wild type mice reduced EAE initiation 
dramatically. However, B10 cells did not suppress ongoing EAE disease. Rather, Treg cell 
numbers expanded significantly within the CNS during disease progression, which paralleled 
their negative regulation of late-phase disease. Likewise, the preferential depletion of B10 cells 
in vivo during disease initiation enhanced EAE pathogenesis, while Treg cell depletion enhanced 
late-phase disease. B10 cells did not regulate T cell proliferation during in vitro assays, but 
significantly altered CD4+ T cell IFN-γ and TNF-α production. Furthermore, B10 cells down-
regulated the ability of DCs to act as antigen-presenting cells and thereby indirectly modulated T 
cell proliferation. Thus, B10 cells predominantly control disease initiation, while Treg cells 
reciprocally inhibit late-phase disease, with overlapping B10 cell and Treg cell functions shaping 




Multiple sclerosis (MS) has been classically viewed as a predominantly T cell-dependent 
autoimmune disease, a feature shared by rheumatoid arthritis, systemic sclerosis, and type 1 
diabetes. This conclusion derives from the finding that the adoptive transfer of T cells from 
diseased animals can initiate disease symptoms in healthy recipients. By contrast, regulatory 
CD4+ T cells (Treg) are critically important for limiting T cell activation during MS and other 
autoimmune diseases (1, 2), in part through their production of IL-10 (3). However, B cells also 
regulate immune responses and can contribute to disease pathogenesis (4, 5) by functioning as 
cellular adjuvants for CD4+ T cell activation (6) and through the production of cytokines that 
regulate T cell function and inflammation (7). Furthermore, recent phase I and II clinical trials in 
MS patients using depleting CD20 mAb (rituximab) suggest that pan-mature B cell depletion has 
clinical efficacy for the treatment of MS (8, 9), in addition to demonstrated efficacy for other 
autoimmune disorders (5). Despite these advances, understanding of the complex mechanisms 
through which B cells influence disease activity in humans and mice remains largely incomplete. 
B cell negative regulation of immune responses has been demonstrated in the mouse 
experimental autoimmune encephalomyelitis (EAE) model of human MS (10-12), and other 
mouse models of autoimmunity and inflammation (7, 12-20). A relatively rare spleen B cell 
subset with IL-10-dependent negative regulatory functions has recently been identified that is 
predominantly contained within the phenotypically-unique CD1dhiCD5+CD19hi spleen B cell 
subpopulation in mice (12, 17-19). A specific subset of the CD1dhiCD5+ B cells can be induced 
to express cytoplasmic IL-10 following 5 h of in vitro stimulation with LPS, PMA, and 
ionomycin, with monensin included in the cultures to block IL-10 secretion (L+PIM stimulation). 
Given that multiple regulatory B cell subsets are likely to exist, as is now well recognized for T 
cells, we have specifically labeled the IL-10-competent CD1dhiCD5+ B cells as B10 cells 
because they appear to only produce IL-10 and they are responsible for most B cell IL-10 
production (21). B10 progenitor (B10pro) cells have also been functionally identified in mice (5, 
21). Spleen B10pro cells are also found within the CD1dhiCD5+ B cell subpopulation, but these 
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cells require 48 h of in vitro stimulation with LPS or through CD40 before they acquire the 
ability to express cytoplasmic IL-10 after 5 h stimulation with L+PIM (21). Although B10 cells 
normally represent only 1-2% of spleen B cells, they dramatically inhibit the induction of 
antigen-specific inflammatory reactions and autoimmunity (12, 17).  
Significant roles for B10 cells and B cells have been reciprocally identified during the 
initiation and progression of EAE (12). Mature B cell depletion in mice before EAE induction 
significantly exacerbates disease symptoms, while B cell depletion during EAE progression 
dramatically inhibits disease symptoms. B10 cell depletion from mice before disease initiation 
accounts for exacerbated disease, which can be ameliorated by the adoptive transfer of spleen 
CD1dhiCD5+ B cells. Similarly, IL-10-deficiency enhances the severity of EAE (22). Thereby, 
the balance between opposing positive and negative regulatory B cell functions shapes the 
normal course of EAE immunopathogenesis.  
Whether and how the regulatory functions of B10 cells and Treg cells overlap or influence 
EAE immunopathogenesis independently has remained unanswered. To address this question, 
the regulatory effects of adoptively transferring increasing numbers of naïve or EAE-sensitized 
B10 cells, or IL-10-deficient CD1dhiCD5+ B cells into wild type mice at various stages of disease 
was evaluated, in addition to depleting Treg cells during both disease initiation and progression. 
Furthermore, we are the first to show in this study that in vivo CD22 mAb treatment 
preferentially depletes spleen B10 cells, which dramatically exacerbates EAE severity during the 
initiation phase of disease. These studies thereby demonstrate that B10 cells have different 
regulatory functions when compared to Treg cells, as they function at different time points 
during EAE initiation and disease progression. Moreover, B10 cells directly influenced the 
production of pro-inflammatory cytokines by CD4+ T cells and suppressed the Ag presenting 
function of DCs. Thereby, independent but overlapping B10 cell and Treg cell functions shape 
the normal course of EAE immunopathogenesis. 
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Methods 
Cell preparation and immunofluorescence analysis 
Single-cell leukocyte suspensions from spleens and peripheral lymph nodes (paired axillary and 
inguinal) were generated by gentle dissection. Blood mononuclear cells were isolated from 
heparinized blood after centrifugation over a discontinuous Lympholyte-Mammal (Cederlane, 
Ontario, Canada) gradient. CNS mononuclear cells were isolated after cardiac perfusion with 
PBS, as described (23). Briefly, CNS tissues were digested with collagenase D (2.5 mg/ml, 
Roche Diagnostics, Mannheim, Germany) and DNaseI (1 mg/ml, Roche Diagnostics) at 37°C for 
45 min. Mononuclear cells were isolated by passing the tissue through 70-mm cell strainers (BD 
Biosciences, San Diego, CA), followed by percoll gradient (70%/37%) centrifugation. 
Lymphocytes were collected from the 37:70% interface and washed.  
Mouse CD20-specific mAb MB20-11 was used as described (24). FITC-, PE-, PE-Cy5-, PE-
Cy7-, or APC-conjugated CD1d (1B1), CD3 (17A2), CD4 (H129.19), CD5 (53-7.3), CD8 (53-
6.7), CD11b (M1/70), CD11c (N418), CD19 (1D3), CD25 (PC61), B220 (RA3-6B2), and 
Thy1.1 (OX-7) mAbs were from BD Biosciences. PE-conjugated IL-10R mAb (1B1.3a) was 
from BioLegend (San Diego, CA). Intracellular staining used mAbs reactive with IL-10 (JES5-
16E3), IFN-γ (XMG1.2), TNF-α (MP6-XT22), and FoxP3 (FJK-16s) (all from eBioscience) and 
Cytofix/Cytoperm kits (BD Biosciences). For T cell intracellular cytokine staining, lymphocytes 
were stimulated in vitro with PMA (50 ng/ml; Sigma, St. Louis, MO) and ionomycin (1 µg/ml; 
Sigma), in the presence of Brefeldin A (BFA, 1 µl/ml; eBioscience) for 5 h before staining. 
Background staining was assessed using non-reactive, isotype-matched control mAbs (Caltag 
Laboratories, San Francisco, CA). For two- to six-color immunofluorescence analysis, single cell 
suspensions (106 cells) were stained at 4°C using predetermined optimal concentrations of mAb 
for 20 min as described (25). Blood erythrocytes were lysed after staining using FACSTM Lysing 
Solution (Becton Dickinson, San Jose, CA). Cells with the forward and side light scatter 
properties of lymphocytes were analyzed using a FACScan flow cytometer (Becton Dickinson) 
or BD FACSCanto™ II (BD Biosciences). 
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Mice and immunotherapy 
C57BL/6 and IL-10-/- (B6.129P2-Il10tmlCgn/J) mice (26) were from The Jackson Laboratory (Bar 
Harbor, ME). CD19-/- and hCD19Tg (h19-1 line) mice were backcrossed with C57BL/6 mice for 
14 and 7 generations, respectively, as described (27, 28). TCRMOG transgenic mice (Thy1.2+, 
provided by Dr. V. K. Kuchroo, Harvard Medical School, Boston, MA) were crossed to 
C57BL/6.Thy1.1 mice to generate Thy1.1-expressing T cells. All mice were bred in a specific 
pathogen-free barrier facility and used at 6-12 wks of age. 
To deplete B10 cells in vivo, sterile CD22 (MB22-10, IgG2c) or isotype-matched mAbs (250 
µg) were injected in 200 ml PBS through lateral tail veins (29). To deplete CD4+CD25+FoxP3+ 
regulatory T cells in vivo, denileukin diftitox (5 µg in 500 ml PBS, Ligand Pharmaceuticals, Inc., 
San Diego, CA) or PBS were injected i.p.. The Duke University Animal Care and Use 
Committee approved all studies. 
 
EAE induction 
Active EAE was induced in 6- to 8-week-old female mice by subcutaneous immunization with 
100 µg of MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK; NeoMPS, San Diego, CA) 
emulsified in CFA containing 200 µg of heat-killed Mycobacterium tuberculosis H37RA (Difco, 
Detroit, MI) on day 0. Additionally, mice received 200 ng of pertussis toxin (List Biological 
Laboratories, Campbell, CA) i.p. in 0.5 ml of PBS on days 0 and 2. Clinical signs of EAE were 
assessed daily with a 0 to 6 point scoring system; 0, normal; 1, flaccid tail; 2, impaired righting 
reflex and/or gait; 3, partial hind limb paralysis; 4, total hind limb paralysis; 5, hind limb 
paralysis with partial fore limb paralysis; 6, moribund state (11). Moribund mice were given 
disease severity scores of 6 and euthanized. Disease scores over the course of the 28 day 
experiments were totaled for each animal, and the mean for the experimental group was 




Following an initial perfusion with PBS, animals were perfused transcardially with 4% 
paraformaldehyde and spinal cords were removed. Tissues were processed and blocked in 
paraffin wax. Two transverse sections of the thoracic and lumber spinal cord were stained with 
H&E and Luxol Fast Blue. The number of inflammatory foci that contained at least 20 cells were 
counted in each H&E–stained section in a blinded fashion. When foci coalesced, estimates were 
made of the number of foci. Areas of demyelination were assessed for Luxol Fast Blue stained 
sections. ImageJ software (NIH, Bethesda, MD) was used to manually trace the total cross-
sectional area and the demyelinated area of each section. Total demyelination was expressed as a 
percentage of the total spinal cord area. 
 
B10 cell Analysis  
Intracellular IL-10 expression was visualized by immunofluorescence staining and analyzed by 
flow cytometry as described (17). Briefly, isolated leukocytes or purified cells were resuspended 
(2 x 106 cells/ml) in complete medium [RPMI 1640 media containing 10% FCS, 200 µg/ml 
penicillin, 200 U/ml streptomycin, 4 mM L-Glutamine, and 5 x 10-5 M 2-mercaptoethanol (all 
from Gibco, Carlsbad, CA)] with LPS (10 µg/ml, Escherichia coli serotype 0111: B4, Sigma), 
PMA (50 ng/ml; Sigma), ionomycin (500 ng/ml; Sigma), and monensin (2 µM; eBioscience) for 
5 h, in 48-well flat-bottom plates. In some experiments, the cells were incubated for 48 h with an 
agonistic anti-mouse CD40 mAb (1 µg/ml; HM40-3 mAb; BD Pharmingen) as described (21). 
For IL-10 detection, Fc receptors were blocked with mouse Fc receptor mAb (2.4G2; BD 
PharMingen) with dead cells detected using a LIVE/DEAD® Fixable Violet Dead Cell Stain Kit 
(Invitrogen-Molecular Probes) before cell surface staining. Stained cells were fixed and 
permeabilized using a Cytofix/Cytoperm kit (BD PharMingen) according to the manufacturer’s 
instructions and stained with PE-conjugated mouse anti-IL-10 mAb. Leukocytes from IL-10-/- 




Real-time reverse transcription PCR Analysis 
Total RNA was extracted from cell sorter purified B cells using Qiagen RNeasy spin columns 
(Qiagen Ltd., Crawley, UK). Random hexamer primers (Promega, Madison, WI) and Superscript 
II RNase H Reverse Transcriptase (Invitrogen, Carlsbad, CA) were used to generate cDNA. IL-
10 transcripts were quantified by real-time PCR analysis using SYBR Green as the detection 
agent. The PCR was performed with the iCycler iQ system (Bio-Rad, Hercules, CA). All 
components of the PCR mix were purchased from Bio-Rad and used according to the 
manufacturer’s instructions. Cycler conditions were one amplification cycle of denaturation at 
95º C for 3 min followed by 40 cycles of 95º C for 10 s, 59º C for 1 min, and 95º C for 1 min. 
Specificity of the RT-PCR was controlled by the generation of melting curves. IL-10 expression 
threshold values were normalized to GAPDH expression using standard curves generated for 
each sample by a series of four consecutive 10-fold dilutions of the cDNA template. For all 
reactions, each condition was performed in triplicate. Data analysis was performed using iQ 
Cycler analysis software. The sense IL-10 primer was 5’-GGTTGCCAAGCCTTATCGGA-3’ 
and the antisense primer was 5’-ACCTGCTCCACTGCCTTGCT-3’. The sense GAPDH primer 
was 5’-TTCACCACCATGGAGAAGGC-3’ and the antisense primer was 5’-
GGCATGGACTGTGGTCATGA-3’. 
 
Lymphocyte subset isolation 
MACS (Miltenyi Biotech, Auburn, CA) was used to purify lymphocyte populations according to 
the manufacturer’s instructions. CD19 mAb-coated microbeads and CD4+ T cell isolation kits 
(Miltenyi Biotech) were used to purify B cells and CD4+ T cells, respectively. When necessary, 
the cells were enriched a second time using a fresh MACS column to obtain >95% cell purities, 
respectively. Spleen DCs were obtained as previously described with minor modifications (30). 
Briefly, spleens were minced and incubated with collagenase D (1 mg/ml; Roche Applied 
Sciences, Indianapolis, IN) and DNaseI (0.2 mg/ml; Roche Applied Sciences) for 30 min at 37°C. 
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Cold EDTA was added to a final concentration of 20 mM and cell suspensions were incubated 
for 5 min at room temperature before filtering through nylon mesh to remove tissue and cell 
aggregates. To enrich for cells with a low buoyant density, cellular suspensions were separated 
over a 30% BSA gradient and cells were collected from the interface. After enrichment, DCs 
were isolated using CD11c mAb-coated microbeads (Miltenyi Biotech).  
 
Cell sorting and adoptive transfer experiments 
Naïve wild type mice, wild type mice with EAE, or IL-10-/- mice with EAE were used as B cell 
donors. Splenic B cells were first enriched using CD19 mAb-coated microbeads (Miltenyi 
Biotech). In addition, CD1dhiCD5+ and CD1dloCD5- B cells were isolated using a FACSVantage 
SE flow cytometer (Becton Dickinson) with purities of 95-98%. After purification, 1x106 cells 
were immediately transferred intravenously into recipient mice. 
 
In vitro T cell, B cell and DC co-culture assays 
Splenic CD1dhiCD5+ or CD1dloCD5- B cells from day 28 EAE mice were purified by cell sorting. 
The sorted cell populations were stimulated with agonistic CD40 mAb for 48 h, with LPS added 
during the final 5 h of culture. TCRMOG CD4+ T cells were purified by MACS, and CFSE labeled. 
CFSE-labeled TCRMOG CD4+ T cells (1x106/ml) were cultured alone or with CD40/LPS-
stimulated CD1dhiCD5+ or CD1dloCD5- B cells (1x106/ml) in the presence of MOG35-55 (25 
µg/ml) for 72 h.  
In additional experiments, splenic CD1dhiCD5+ or CD1dloCD5- B cells from day 28 EAE 
mice were purified by cell sorting. The sorted cell populations were stimulated with agonistic 
CD40 mAb for 48 h, with LPS added during the final 5 h of culture. Splenic DCs from day 10 
EAE mice were purified by MACS and cultured (1x106/ml) with CD40 mAb/LPS-stimulated 
CD1dhiCD5+ or CD1dloCD5- B cells (1x106/ml) in the presence of MOG35-55 (25 µg/ml) for 72 h. 
DCs were purified by cell sorting after 72 h co-cultures with B cells, and then cultured 




All data are shown as means (±SEM). The significance of differences between sample means 
was determined using the Student’s t test. 
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Results 
B10 and Treg cell expansion during EAE 
B10 cells and the spleen CD1dhiCD5+ B cell subpopulation are significantly expanded in 
autoimmune prone mice (21). To determine whether B10 cells expand during EAE, B10 cell 
numbers were quantified after L+PIM stimulation and staining for cytoplasmic IL-10 expression. 
After MOG35-55 immunization, spleen CD1dhiCD5+ B cell frequencies and numbers were 
significantly increased on days 7, 21, and 28 in contrast to naïve mice (Fig. 1A). B10 cell 
frequencies and numbers were also significantly increased on days 7, 21, and 28 after MOG35-55 
immunization (Fig. 1B). Increased B cell IL-10 production paralleled B10 cell frequencies (Fig. 
1C), while immunizations with CFA alone had no effect on B10 cell numbers (Fig. 1D). Thus, 
there was an initial increase in B10 cell numbers and IL-10 transcripts following MOG35-55 
immunization, which resolved, with a subsequent increase during EAE disease onset and 
resolution. 
Since Treg cells negatively regulate EAE symptoms (2), spleen CD25hiFoxP3+CD4+ Treg 
cell numbers were also quantified. Treg cell frequencies and numbers were only significantly 
higher by day 21 and 28 after MOG35-55 immunization in contrast to naïve mice (Fig. 1E). 
Thereby, B10 cell numbers increased during both the initiation and late phases of EAE 
progression, while Treg cell numbers were only increased during late-phase EAE. 
 
B10 cell regulation of EAE 
To determine whether quantitative differences in spleen B10 cell numbers influenced EAE, 
disease initiation and progression were compared in wild type, CD19-deficient (CD19-/-), and 
human CD19 transgenic (hCD19Tg) mice that overexpress CD19. Spleen CD1dhiCD5+ B cells 
were present at similar frequencies and numbers in wild type and IL-10-/- mice (Fig. 2A), as 
described (17). In hCD19Tg mice, CD1dhiCD5+ B cell frequencies and numbers were 4.4- and 
1.6-fold higher than in wild type littermates, respectively. B10 cell frequencies and numbers 
were also 5.6- and 1.8-fold higher in hCD19Tg mice, respectively (Fig. 2B). By contrast, 
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CD1dhiCD5+ B cell frequencies (93% decrease, p<0.01) and numbers (92% decrease, p<0.01) 
were reduced in CD19-/- mice when compared with wild type mice, while B10 cell frequencies 
and numbers were 62% and 76% lower, respectively (p<0.01). Thus, hCD19Tg and CD19-/- mice 
provided an optimal model system for assessing the importance of B10 cell numbers during EAE. 
EAE responses were assessed in MOG35-55-immunized CD19-/-, hCD19Tg, and wild type 
mice. EAE symptoms first appeared around day 11 after immunization of wild type mice and 
peaked around day 18, then declined gradually (Fig. 2C). By contrast, EAE severity was 
significantly diminished in hCD19Tg mice (cumulative EAE score, 17.5±4.7) when compared 
with wild type mice (38.1±5.0, p<0.05). By contrast, EAE severity was significantly enhanced in 
CD19-/- mice (62.5±3.3, p<0.005), as reported (31). Thus, enhanced or reduced B10 cell numbers 
in mice inversely paralleled their disease symptoms. 
To confirm that B10 cells regulated EAE responses in CD19-/- mice, spleen CD1dhiCD5+ or 
CD1dloCD5- B cells were purified from naive wild type mice and adoptively transferred (106 per 
recipient) into CD19-/- mice 24 h before immunization with MOG35-55. CD1dhiCD5+ B cells were 
used for the adoptive transfer experiments since this small subpopulation contains both the B10 
and B10pro cell subsets and can be identified without in vitro stimulation (17). Transferring 
CD1dhiCD5+ B cells into CD19-/- mice significantly reduced EAE severity (cumulative EAE 
score, 40.6±5.0) to levels observed in wild type mice (37.2±5.6, Fig. 2D left panel) when 
compared with CD19-/- mice (62.2±3.9, p<0.01). By contrast, the adoptive transfer of 
CD1dloCD5- B cells into CD19-/- mice before EAE induction did not affect EAE severity 
(61.8±5.1, Fig. 2D right panel). Furthermore, the adoptive transfer of CD1dhiCD5+ B cells 
purified from IL-10-/- mice did not affect EAE severity (Fig. 2D). Thus, B10 cells negatively 
regulated EAE development through the production of IL-10, with increased B10 cell numbers 
significantly reducing disease severity.  
 
Blocking CD22 ligand binding depletes B10 cells in vivo 
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To determine whether endogenous B10 cells regulate EAE, methods were developed to 
preferentially deplete B10 cells. The in vivo treatment of mice with mAbs that bind CD22 ligand 
binding domains preferentially depletes splenic B cells with a “marginal zone” phenotype, while 
leaving follicular B cells largely intact (29). Since B10 and “marginal zone” B cells share some 
overlapping cell surface markers (17), the ability of CD22 mAb (MB22-10) to deplete B10 cells 
in vivo was quantified. Remarkably, CD22 mAb treatment reduced both the frequency (86%) and 
number (90%) of CD1dhiCD5+ spleen B cells by day 7 (Fig. 3A). CD22 mAb treatment also 
reduced both the frequency (48%) and number (54%) of spleen B10 cells by day 7, while control 
mAb treatment was without effect. Thereby, CD1dhiCD5+ B cells and B10 cells could be 
preferentially removed without eliminating the majority of spleen B cells. 
 
B10 cells regulate EAE initiation while Treg cells regulate late-phase EAE 
The functional contributions of B10 cells to EAE initiation and pathogenesis were measured 
after depleting B10 cells using CD22 mAb. First, mice were given CD22 mAb 7 days before and 
0, 7, 14, and 21 days after EAE induction in order to deplete B10 cells before and during EAE 
onset. B10 cell depletion did not accelerate disease onset, but made disease severity significantly 
worse (cumulative EAE score, 52.3±4.4) in comparison with control mAb-treated littermates 
(32.0±4.3; p<0.01; Fig. 3B). In fact, 20% of the CD22 mAb-treated mice became moribund and 
were euthanized. Mice were also given CD22 mAb on days 7, 14 and 21 after MOG35-55 
immunization, which increased disease severity (44.8±2.08) in comparison with control mAb-
treated littermates (35.1±2.6). B10 cell depletion in mice given CD22 mAb on days 14 and 21 
after MOG35-55 immunization did not alter disease severity (35.1±2.3) in comparison with control 
mAb-treated littermates (30.9±3.3). B10 cell depletion in mice given CD22 mAb on only day 21 
did not alter disease severity. These findings argue that B10 cell regulatory function is critical 
during disease initiation, but not after disease onset. 
Treg cell depletion before MOG35-55 immunization can increase the severity of EAE, while 
Treg cells accumulate in the CNS during the recovery phase of disease (32-35). Therefore, the 
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functional contributions of Treg cells to EAE initiation and pathogenesis were measured after 
their in vivo depletion. CD25 mAb was not used for depleting Treg cells since persistent mAb 
can deplete or inhibit the expansion of activated T cells expressing CD25 and thereby influence 
EAE pathogenesis independent of Treg depletion. Rather, denileukin diftitox was used, a fusion 
protein of IL-2 and diptheria toxin that binds to Treg cells expressing high affinity CD25 (36-38). 
Denileukin diftitox has limited effects on subsequently activated effector T cells due to its short 
half-life in vivo. Spleen CD25hiFoxP3+CD4+ Treg cells were maximally reduced 3 days after 
denileukin diftitox injection, as previously reported (38), but spleen CD25hiFoxP3+CD4+ Treg 
cells had returned by day 6 after the initial injection. Therefore, multiple denileukin diftitox 
injections were given. Treg cell numbers were significantly reduced (60%) in mice given 
denileukin diftitox 1, 4 and 7 days before Treg cell numbers were quantified (Fig. 3C). For Treg 
cell depletion before EAE onset, mice were given denileukin diftitox 1, 4, 7, 10, and 13 days 
after MOG35-55 immunization. This Treg cell depletion strategy delayed EAE onset by 2 days, 
but the severity of disease symptoms was not altered (cumulative EAE score, 29.6±5.5) in 
comparison with PBS-treated littermates (33.6±5.7; Fig. 3D). For Treg cell depletion after EAE 
onset, mice were given denileukin diftitox 14, 17, 20, 23, and 26 days after EAE induction. Late-
phase Treg cell depletion worsened disease (54.0±4.4) significantly with 20% of the treated mice 
becoming moribund in comparison with PBS-treated littermates (35.6±5.0, p<0.05). Thus, B10 
cell function was important for regulating EAE induction, while Treg cell function was important 
for regulating late-phase disease. 
 
Treg cells dominate the CNS after EAE development 
Since B10 cells regulated EAE induction, while Treg cell function regulated late-phase disease, 
the relative frequencies of B10 and Treg cells within the CNS, inguinal and axillary lymph nodes 
draining the site of MOG immunization, and blood were compared. Within the CNS, B10 cell 
frequencies relative to other B cells did not change significantly during EAE development, 
although B10 cell numbers were significantly increased on days 21 and 28 after MOG35-55 
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immunization (Fig. 4A, left panels). By contrast, CNS-infiltrating Treg cell frequencies relative 
to CD4+ T cells and numbers were dramatically increased on days 7, 21, and 28 after MOG35-55 
immunization relative to naïve mice (Fig. 4A, right panels). Lymph node B10 cell frequencies 
were slightly increased by 28 days after MOG35-55 immunization in contrast to naïve mice, while 
B10 cell numbers were significantly increased on days 21 and 28 after MOG35-55 immunization 
(Fig. 4B, left panels). Treg cell frequencies within lymph nodes were significantly increased on 
days 21 and 28 after MOG35-55 immunization in contrast to naïve mice, while Treg cell numbers 
were significantly increased during all stages of EAE (Fig. 4B, right panels). In blood, B10 cell 
frequencies and numbers were significantly increased on 28 days after MOG35-55 immunization 
(Fig. 4C, left panels). However, circulating Treg cell frequencies and numbers were not changed 
during the course of EAE (Fig. 4C, right panel). As a consequence, Treg cells far outnumbered 
B10 cells within CNS tissues after EAE development, although the relative numbers of B10 and 
Treg cells within the spleen and lymph nodes were essentially unchanged during the course of 
EAE (Fig. 4D). By contrast, blood B10 cell numbers increased gradually relative to Treg cells 
during EAE progression. Thus, B10 cells were far more prevalent than Treg cells within the CNS 
before disease initiation, with Treg cells dominating during late-phase EAE.  
 
Adoptively transferred B10 cells inhibit EAE progression 
The effect of increasing B10 cell numbers in wild type mice on EAE responses was assessed 
using adoptive transfer experiments. Spleen CD1dhiCD5+ B cells and CD1dloCD5- B cells were 
purified from naive mice (Fig. 5A, left panels), and transferred into mice that were immunized 
with MOG35-55 24 h after the transfer. In these adoptive transfer experiments, a total of 1.23 x 105 
of the transferred CD1dhiCD5+ B cells or 0.05 x 105 of the transferred CD1dloCD5- B cells 
expressed cytoplasmic IL-10 after 5 h in vitro stimulation with L+PIM in two independent 
experiments. In one of two experiments with identical results, the adoptive transfer of 
CD1dhiCD5+ B cells from naive mice reduced disease severity (cumulative EAE score, 30.8±2.5) 
in comparison with mice given CD1dloCD5- B cells (42.6±4.5), but this effect was not 
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statistically different from EAE induction or progression in PBS-treated littermates (36.6±3.8; 
Fig. 5C, upper-left panel). Therefore, spleen CD1dhiCD5+ B cells and CD1dloCD5- B cells were 
purified from mice with EAE on day 28 after MOG35-55 immunization. The frequency of B10 
cells within the CD1dhiCD5+ B cell subsets were comparable when the donors were either naive 
mice (Fig. 5A) or mice with EAE (day 28; Fig. 5B, middle panels). Thereby, a total of 1.27 x 105 
of the transferred CD1dhiCD5+ B cells or 0.05 x 105 of the transferred CD1dloCD5- B cells 
expressed cytoplasmic IL-10 after 5 h stimulation with L+PIM in two independent experiments. 
In one of two experiments with identical results, transferring CD1dhiCD5+ B cells purified from 
mice with EAE significantly reduced EAE severity (31.6±4.1; day 13-18, p<0.05) in recipients 
when compared with littermates given CD1dloCD5- B cells (51.4±4.5) or PBS-treated littermates 
(43.4±4.7; Fig. 5C, upper-second panel). Thus, providing naïve mice with B10 cells from 
antigen-primed mice significantly reduced EAE symptoms, while more modest effects were 
obtained when the B10 cells were isolated from naïve mice. 
The spleen CD1dhiCD5+ B cell subset contains B10pro cells that become competent to 
express IL-10 after in vitro CD40 engagement for 48 h to induce their maturation into IL-10-
competent B10 cells (21). The CD1dhiCD5+ B cell subset from naïve mice or mice with EAE 
(day 28) normally contains ~12% IL-10+ B10 cells after 5 h of L+PIM stimulation (Fig. 5A-B). 
However, after 48 h of agonistic CD40 mAb stimulation, ~40% of the purified CD1dhiCD5+ B 
cells expressed cytoplasmic IL-10, whereas <2% of purified CD1dloCD5- B cells produced IL-10 
(Fig. 5B, right panels). Thereby, the frequencies of IL-10-competent B10 cells among 
CD1dhiCD5+ B cells can be enhanced significantly by B10pro cell maturation in vitro.  
For subsequent adoptive transfer experiments, CD1dhiCD5+ and CD1dloCD5- B cells were 
purified from mice with EAE and stimulated with agonistic CD40 mAb for 48 h, with LPS added 
during the final 5 h of culture. In these adoptive transfer experiments, a total of 3.95 x 105 of the 
transferred CD1dhiCD5+ B cells or 0.19 x 105 of the transferred CD1dloCD5- B cells expressed 
cytoplasmic IL-10 in vitro after 5 h stimulation with L+PIM in two independent experiments. In 
one of two experiments with identical results, transferring CD40/LPS-stimulated CD1dhiCD5+ B 
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cells dramatically inhibited EAE progression (cumulative EAE score, 15.6±6.9; day 12-22, 
p<0.05) in comparison with PBS-treated littermates (42±4, p<0.05), while CD1dloCD5- B cells 
did not (42±6, Fig. 5C, lower-left panel). However, inhibition of disease was only observed 
when the transferred cells were given before MOG35-55 immunization of recipients, but not on 
days 7 or 14 after immunization (Fig. 5C, lower-second and third panels). Furthermore, 
CD40/LPS-stimulated CD1dhiCD5+ B cells purified from IL-10-/- mice with EAE (day 28) did 
not affect EAE severity in wild type recipients (Fig. 5C, lower-right panel). Thus, CD40/LPS-
stimulated CD1dhiCD5+ B cells optimally inhibited EAE initiation in an IL-10-dependent manner. 
 
Adoptively transferred B10 cells inhibit leukocyte infiltration into the CNS 
B cell depletion before MOG35-55 immunization exacerbates EAE and results in higher numbers 
of CD4+ T cells within the CNS, while B cell depletion following disease initiation reduces 
CD4+ T cell infiltration into the CNS (12). Whether the adoptive transfer of B10 cells from EAE 
mice inhibited T cell infiltration into the CNS of MOG35-55-immunized mice was therefore 
assessed. CNS tissues were collected on day 18 from groups of mice that had been given PBS, or 
CD40/LPS-stimulated CD1dhiCD5+ or CD1dloCD5- B cells from EAE mice (day 28), and were 
examined by immunofluorescence staining of lymphocytes or quantitative microscopy. 
Remarkably, CD40/LPS-stimulated CD1dhiCD5+ B cell transfers significantly reduced both Treg 
and CD4+ T cell numbers within the CNS, while CD1dloCD5- B cells were without effect (Fig. 
6A). Spleen Treg and CD4+ T cell numbers were not changed among these groups. As quantified 
by microscopy, CD40/LPS-stimulated CD1dhiCD5+ B cell transfers reduced leukocyte 
infiltration (84% decrease thoracic, 84% lumbar; Fig. 6B) and significantly reduced 
demyelination (93% decrease thoracic, 88% lumbar; Fig. 6C) within CNS tissues when 
compared with mice given PBS (p<0.01, Fig. 6D). Thus, adoptively transferred CD1dhiCD5+ B 
cells had profound effects on Treg cell and leukocyte infiltration into the CNS. 
 
B10 cells do not inhibit T cell proliferation, but regulate their cytokine production 
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In vitro T cell-B cell co-culture systems were developed to determine how B10 cells could 
regulate T cell mediated autoimmune disease in vivo. First, purified spleen CD1dhiCD5+ B cells 
or CD1dloCD5- B cells were stimulated with agonistic CD40 mAb (48 h) and LPS (last 5 h of 
culture), washed extensively, and added to cultures containing MOG35-55 and CFSE-labeled 
CD4+ T cells from TCRMOG transgenic mice whose CD4+ T cells respond to MOG35-55 peptide 
(39). CFSE dilution was assessed 72 h later as a marker for T cell proliferation. TCRMOG CD4+ T 
cells cultured without B cells or without MOG35-55 added to the cultures did not proliferate (Fig. 
7A, data not shown). However, TCRMOG CD4+ T cells cultured with either CD1dhiCD5+ or 
CD1dloCD5- B cells proliferated equally well in response to MOG35-55. Thus, B10 cells did not 
regulate T cell proliferation in these in vitro assays. However, when the TCRMOG CD4+ T cells 
were co-cultured with B cells in the presence of MOG35-55 there were significant differences in T 
cell cytokine induction observed following PMA, ionomycin, and brefeldin A stimulation during 
the final 5 h of culture. TCRMOG CD4+ T cells cultured with CD1dhiCD5+ B cells had 
dramatically reduced IFN-γ and TNF-α production when compared with TCRMOG CD4+ T cells 
that were cultured with CD1dloCD5- B cells (Fig. 7B). These changes depended on B cell IL-10 
production, since CD1dhiCD5+ B cells from IL-10-/- mice did not affect IFN-γ or TNF-α 
production by TCRMOG CD4+ T cells. IL-10 production by TCRMOG CD4+ T cells was not 
significantly changed in these culture systems. Thus, B10 cell IL-10 can regulate antigen-specific 
T cell cytokine production. 
 
B10 cells regulate antigen-presentation by DCs in vitro 
IL-10R expression is heterogeneous among cells of the immune system (40). Therefore, IL-10R 
expression by splenic DCs, macrophages, B cells, CD4+ T cells, and CD8+ T cells from wild type 
mice was assessed. IL-10R expression was highest on DCs and macrophages, with modest 
expression by CD4+ T cells, CD8+ T cells, and B cells (Fig. 7C). IL-10R expression was not 
increased on any of these leukocyte subpopulations during the course of EAE (day 7).  
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Since high IL-10R expression by DCs may render them more sensitive to the regulatory 
effects of IL-10 than CD4+ T cells, a role for B10 cells in regulating DC activation of CD4+ T 
cells was assessed. Briefly, purified splenic CD1dhiCD5+ or CD1dloCD5- B cells from mice with 
EAE (day 28) were stimulated with agonistic CD40 mAb for 48 h, with LPS added during the 
final 5 h of culture. Purified splenic DCs from mice with EAE (day 10) were then co-cultured 
with the CD40/LPS-stimulated CD1dhiCD5+ or CD1dloCD5- B cells in the presence of MOG35-55. 
After 72 h of culture, the DCs were purified by cell sorting, and cultured with TCRMOG CD4+ T 
cells for 72 h. The TCRMOG CD4+ T cells were then stained for CD4 and Thy1.1 expression and 
analyzed for CFSE dilution. In cultures where the TCRMOG CD4+ T cells were cultured with DCs 
co-cultured with CD1dhiCD5+ B cells, the intensity of CFSE staining was significantly higher 
and the percentage of dividing TCRMOG CD4+ T cells was significantly reduced when compared 
to DCs cultured with CD1dloCD5- B cells (p<0.05; Fig. 7D). By contrast, culturing DCs with 
CD1dhiCD5+ B cells from IL-10-/- mice did not affect their antigen-presenting ability in this T 
cell activation assay. Thus, IL-10-competent CD1dhiCD5+ B10 cells were able to regulate the 
antigen-presenting capability of DCs. 
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Discussion 
These studies reveal that B10 cells predominantly reduce disease severity during EAE 
initiation through the production of IL-10, while Treg cells reciprocally inhibit late-stage EAE 
immunopathogenesis (Fig. 3). Remarkably, the early expansion in B10 cell numbers and IL-10 
production following MOG35-55 immunization parallels B10 cell regulation of disease initiation 
(Fig. 1A-C), while Treg cell expansion during disease progression parallels their negative 
regulation of late-stage disease (Fig. 1E). The current studies also demonstrate that numbers of 
endogenous or adoptively transferred B10 cells directly influences the outcome of EAE 
pathogenesis. Specifically, mice with decreased B10 cell numbers exhibited enhanced disease 
severity relative to wild type mice, while mice with enhanced B10 cell numbers had reduced 
EAE severity (Fig. 2). Likewise, the preferential depletion of B10 cells in vivo by CD22 mAb 
treatment enhanced EAE pathogenesis (Fig. 3A-B). By contrast, the adoptive transfer of antigen-
sensitized B10 cells into naïve recipients before MOG35-55 immunizations inhibited EAE 
pathogenesis through the production of IL-10, while increasing B10 cell numbers in mice 
exhibiting disease symptoms was without significant effect (Fig. 5). Thus, regulatory B10 cells 
and Treg cells have independent roles in controlling EAE initiation and late-phase 
immunopathogenesis. 
The timing of differential B10 cell and Treg cell expansion within tissues parallels their 
importance during disease initiation and late-phase EAE pathogenesis. B10 cell and CD1dhiCD5+ 
B cell numbers expanded significantly (~70% increase) by 7 days after MOG35-55 immunization, 
decreased, and expanded to even higher levels during the course of disease progression, with 
maximum numbers (~130% increase) accumulating as disease resolved (Fig. 1A-B). IL-10 
production by spleen B cells and blood B10 cell numbers followed a similar course of expansion, 
contraction, and expansion (Fig. 4C, Fig. 1C), while lymph node B10 cell numbers expanded 
most significantly during disease resolution (Fig. 4B). By contrast, Treg cell numbers did not 
increase following MOG35-55 immunization, but increased gradually with EAE progression (Fig. 
2C). On a relative frequency basis, B10 cells were 4-times more prevalent in the CNS than Treg 
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cells before MOG35-55 immunization and their numbers remained constant except during disease 
resolution (Fig. 4A). By contrast, Treg cells were 19-fold more prevalent in the CNS on day 28 
than B10 cells, while spleen B10 cell and Treg cell frequencies were equal throughout the course 
of EAE (Fig. 4D). The absence of Treg cell expansion during EAE initiation provides the likely 
mechanistic explanation for why B cell depletion by CD20 mAb or B10 cell depletion by CD22 
mAb before MOG35-55 immunization exacerbated EAE (Fig. 3B, ref. 12). Reciprocally, the 
dramatic expansion of Treg cells within the CNS during EAE progression explains why the 
removal of B cells or B10 cells at this time does not enhance disease pathogenesis. This was 
confirmed when denileukin diftitox-induced Treg cell depletion had no effect on disease 
initiation but only exacerbated late-phase disease (Fig. 3D). Denileukin diftitox treatment also 
suppresses active EAE in rats when given early, but results in lethal disease if given later (41). In 
contrast to the current studies in wild type mice, it has been previously reported that IL-10-
producing B cells contribute to EAE recovery in mice that are genetically B cell-deficient (11). 
However, this is explained by the finding that B cell deficiency delays the emergence of Treg 
cells and IL-10 in the CNS during EAE (42). Thereby, the relative balance between B10 cell and 
Treg cell numbers in wild type mice during the course of EAE has dramatic effects on disease 
outcome. 
Antigen-specific B10 cell expansion is required to elicit B10 cell regulatory functions and a 
diverse repertoire of B cell antigen receptors is required for B10 cell development (12, 17, 21). 
Thereby, the ability of B10 cells to rapidity expand during EAE initiation and to quickly inhibit 
disease severity suggests that a sufficient pool of Ag-specific B10 cells exists naturally that are 
rapidly mobilized to inhibit inflammation. This is supported by adoptive transfer experiments 
where MOG35-55-primed CD1dhiCD5+ B cells, but not naïve CD1dhiCD5+ B cells, inhibited EAE 
development (Fig. 5). The spleen of adult C57BL/6 mice normally contains 0.5-1.0 x 106 B10 
cells and 3.5-4.5 x 106 B10+B10pro cells (43). Remarkably, the adoptive transfer of 1.0 x 106 
CD1dhiCD5+ spleen B cells containing ~1.2 x 105 B10 cells from naïve mice reduced EAE 
severity, while 1.0 x 106 CD1dhiCD5+ spleen B cells containing only ~1.3 x 105 B10 cells from 
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mice with EAE significantly reduced EAE severity (Fig. 5C). The transfer of 1.0 x 106 
CD1dhiCD5+ spleen B cells from mice with EAE containing ~3.9 x 105 in vitro-matured 
B10+B10pro cells was able to dramatically reduce EAE severity. Thereby, the identification of 
antigen-specific B10 cells may significantly reduce the number of adoptively transferred B10 
cells needed for inhibiting EAE in vivo. Importantly, the adoptive transfer of IL-10-/- 
CD1dhiCD5+ B cells did not affect EAE responses under any conditions tested. Thus, in addition 
to their pre-programmed ability to rapidly proliferate in response to external stimuli (21) and 
produce IL-10 (17), the size of the endogenous B10 and B10pro cell pool is a critical factor for 
regulating the magnitude of acute inflammation and the induction of autoimmunity. 
B10 cells regulate T cell-mediated inflammatory responses and EAE through IL-10-
dependent mechanisms (12, 17). The current studies demonstrated that B10 cells did not directly 
regulate T cell proliferation (Fig. 7A), but significantly reduced CD4+ T cell IFN-γ and TNF-α 
production during in vitro assays (Fig. 7B). By contrast, non-CD1dhiCD5+ B cells were not able 
to influence CD4+ T cell IFN-γ and TNF-α production. Lampropoulou et al. have shown that 
tissue culture supernatant fluid from LPS-stimulated spleen B cells does not suppress CD4+ T 
cell proliferation in response to CD3 mAb stimulation in vitro, but is able to suppress IFN-g 
secretion by T cells stimulated with CpG-stimulated DC (44). Treg cells isolated from the CNS 
are also able to suppress T cell IFN-γ production in response to MOG35-55 (45). Furthermore, B10 
cells may also down-regulate the ability of DCs to act as antigen-presenting cells and thereby 
indirectly modulate T cell proliferation (Fig. 7). Consistent with these findings, others have 
found that IL-10 suppresses the proliferation of Ag-specific CD4+ T cells by inhibiting the Ag-
presenting capacity of monocytes and DCs (46) as well as inhibiting pro-inflammatory cytokine 
production by monocytes and macrophages (47). Lampropoulou et al. have also shown that 
tissue culture supernatant fluid from LPS-stimulated spleen B cells is able to suppress T cell 
activation by CpG-stimulated DCs through IL-10-dependent pathways (44). IL-10 was initially 
associated with Th2 cells and was described to inhibit Th1 cytokine production (48-50). 
However, IL-10 is not only involved in the inhibition of Th1 polarization, but also prevents Th2 
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responses and exerts anti-inflammatory and suppressive effects on most hematopoietic cells. IL-
10 produced by monocytes and cells other than T cells is required to maintain Treg cell 
suppressive function and to maintain expression of the FoxP3 transcription factor in mice with 
colitis (51). However, the adoptive transfer of in vitro-matured spleen B10+B10pro cells from 
mice with EAE significantly reduced the number of Treg cells within the CNS, in addition to 
reducing the number of inflammatory foci (Fig. 6). It is thereby unlikely that IL-10 produced by 
B10 cells contributes significantly to Treg cell maintenance during inflammation in vivo. 
However, future studies will be needed to determine whether B10 cells regulate cytokine 
production by the wide variety of additional T cell subsets that are known to critically influence 
EAE pathogenesis. 
CD22 mAb treatment preferentially depleted spleen B10 cells and exacerbated EAE disease 
severity (Figs. 3A-B). Since the CD22 mAb used in the current study blocks CD22 ligand 
binding, it is possible that CD22 engagement is particularly essential for the survival of B10 cells 
within lymphoid tissues (29, 52). How these mouse findings relate to the therapeutic benefits of a 
CD22 mAb, epratuzumab, currently in clinical trials is unknown. However, CD22 mAb 
treatment only exacerbated EAE severity when given to mice before disease induction and did 
not exacerbate symptoms in mice with ongoing disease. Thereby, CD22 mAb treatment may not 
worsen disease in patients diagnosed with autoimmunity. However, there may be instances 
where B10 cell depletion would be advantageous such as in the treatment of cancers, 
immunosuppression, or vaccination. For example, Treg cell depletion using denileukin diftitox 
has demonstrated efficacy in the treatment of hematologic malignancies and solid tumors that do 
not express CD25, in autoimmune disease, and in enhancing vaccine-mediated T cell immunity 
(37, 38, 53, 54). Although therapeutic B cell depletion has shown clinical efficacy in treating MS 
patients (8, 9), B cell depletion may also remove B10 cells and exacerbate MS severity, induce 
disease in some undiagnosed cases, or promote relapses in some rare cases (55). As examples, B 
cell depletion was recently suggested to exacerbate ulcerative colitis and trigger psoriasis, 
diseases that are thought to be predominately T cell-dependant (56, 57). In addition, one case 
24 
report suggests that B cell depletion might have induced relapses in a patient with an 18-year 
history of MS who developed anti-myelin-associated glycoprotein polyneuropathy that was 
treated with rituximab (58). Thereby, the therapeutic benefits of B10 cell and B cell depletion in 
humans may also depend on the relative contributions and timing of these opposing B cell 
functions during immune responses. 
The current studies demonstrate that B10 cells expand during autoantigen-specific adaptive 
immune responses and that adoptively transferred B10 cells are sufficient to blunt EAE induction. 
Thus, the development of B10 cell-based therapies may be ideal for treating some autoimmune 
diseases. This could include the isolation, expansion, and return of expanded B10 cells isolated 
from Ag-sensitized individuals. Other studies have also shown that the adoptive transfer of B 
cells can have a therapeutic benefit in the treatment of mice with EAE, type 1 diabetes, and 
collagen-induced arthritis (11, 12, 59, 60). It may also be possible to identify pathways that 
regulate B10 cell activation, expansion, and function, which will allow this potent B cell subset 
to be manipulated for therapeutic benefit. In support of this, B cell IL-10 production in MS 
patients is significantly lower than in healthy controls and is up-regulated following therapy (61). 
In addition, helminth infections induce regulatory B cells in MS patients and suppress disease 
activity (62), which may explain environment-related suppression of MS in areas with low 
disease prevalence. While the current studies further reveal the regulatory complexities of the 
immune system, they also open the door for the identification of B10 cell-directed therapies that 
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Figure Legends 
Figure 1. B10 cell and Treg cell numbers increase during EAE. (A) CD1dhiCD5+ B cell 
frequencies and numbers increase during the course of EAE. Splenocytes were isolated from 
mice before, and 7, 14, 21 or 28 days after MOG35-55 immunization and analyzed for CD1d, CD5, 
and CD19 expression by immunofluorescence staining with flow cytometry analysis. 
Representative results demonstrate the frequency of CD1dhiCD5+ B cells within the indicated 
gates among total CD19+ B cells. Bar graphs indicate mean (±SEM) percentages and numbers of 
CD1dhiCD5+ B cells. (B) IL-10+ B10 cell frequencies and numbers increase during the course of 
EAE. Splenocytes were cultured with L+PIM for 5 h, stained with CD19 mAb, permeabilized, 
and stained using IL-10 mAb with flow cytometry analysis. Representative results demonstrate 
the frequency of IL-10-producing cells within the indicated gates among total CD19+ B cells. 
Bar graphs indicate mean (±SEM) percentages and numbers of B cells that produced IL-10. (C) 
B cell IL-10 transcript expression during EAE. RNA was isolated from splenic CD19+ B cells 
purified from mice before, and 7, 14, 21 or 28 days after MOG35-55 immunization by MACS 
beads (purities >99%). Values represent relative mean IL-10 transcript levels normalized to 
GAPDH transcript levels (±SEM) as quantified by real-time reverse transcription PCR analysis. 
(D) CFA immunization does not affect IL-10+ B10 cell frequencies or numbers. Spleen B10 cell 
frequencies were examined before and after immunization with CFA emulsified in an equal 
volume of PBS as outlined in (B). (E) CD4+CD25+FoxP3+ T cell frequencies and numbers 
increase during the course of EAE. Splenocytes were stained with CD4 and CD25 mAbs, 
permeabilized, and stained using FoxP3 mAb with flow cytometry analysis. Representative 
results demonstrate the frequency of CD4+CD25+FoxP3+ T cells within the indicated gates 
among total CD4+ T cells. Bar graphs indicate mean (±SEM) percentages and numbers of 
CD4+CD25+FoxP3+ T cells. (A-E) Bar graphs indicate results from one of two independent 
experiments with ≥5 mice in each group. Horizontal dashed lines are provided for reference to 
naïve mice. Significant differences between means of naïve and immunized mice are indicated; 
*p<0.05, **, p<0.01. 
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Figure 2. B10 cell frequencies significantly influence EAE severity. (A) CD1dhiCD5+ B cell 
frequencies and numbers in wild type, hCD19Tg, CD19-/-, and IL-10-/- mice. Representative 
results demonstrate the frequency of spleen CD1dhiCD5+ B cells within the indicated gates 
among total CD19+ or CD20+ B cells. Bar graphs indicate mean (±SEM) percentages and 
numbers of CD1dhiCD5+ B cells in one of two independent experiments with 3 mice in each 
group. (B) IL-10+ B10 cell frequencies and numbers in wild type, hCD19Tg, CD19-/-, and IL-10-
/- mice. Representative results demonstrate the frequency of spleen IL-10-producing cells within 
the indicated gates among total CD19+ or CD20+ B cells. Bar graphs indicate mean (±SEM) 
percentages and numbers of B cells that produced IL-10. (A-B) Values in each group represent 
results from 6 mice from two pooled independent experiments. Significant differences between 
means from wild type and other mouse groups are indicated; *p<0.05, **, p<0.01. (C) EAE 
progression and severity in wild type, CD19-/-, and hCD19Tg mice immunized with MOG35-55 on 
day 0 and scored daily thereafter for EAE disease severity. Values represent mean (±SEM) EAE 
clinical scores from ≥5 mice in each group, with similar results obtained in 2 independent 
experiments. Significant differences between wild type and mutant mice groups are indicated; 
*p<0.05 (wild type versus hCD19Tg mice), †p<0.05 (wild type versus CD19-/- mice). (D) 
Adoptively transferred CD1dhiCD5+ B cells reduce EAE severity in CD19-/- mice. Splenic 
CD1dhiCD5+ or CD1dloCD5- B cells were purified from naïve wild type or IL-10-/- mice by cell 
sorting. Wild type and CD19-/- recipient mice were either given PBS, purified CD1dhiCD5+ or 
CD1dloCD5- B cells 1 day (arrowheads) before MOG35-55 immunizations. Values represent mean 
(±SEM) results from ≥5 mice in each group, with similar results obtained in 2 independent 
experiments. Significant differences between the means of EAE clinical scores are indicated: 
*p<0.05 (black diamond versus white diamond). 
 
Figure 3. B10 cells and Treg cells cooperatively regulate EAE severity. (A) B10 cell depletion 
in vivo. Spleen CD1dhiCD5+ and IL-10+ B cell frequencies were determined in wild type mice 7 
36 
days after MB22-10 or control mAb treatments (250 µg/mouse). Upper panels, representative 
results demonstrate the frequency of CD1dhiCD5+ B cells within the indicated gates among total 
CD19+ B cells. Lower panels, representative results demonstrate the frequencies of IL-10+ cells 
within the indicated gates among total CD19+ B cells. Bar graphs indicate mean (±SEM) 
percentages and numbers of CD1dhiCD5+ or IL-10+ B cells from 6 mice in each group from two 
pooled independent experiments. Significant differences between MB22-10 or control mAb 
treatment groups are indicated; **, p<0.01. (B) Early B10 cell deletion exacerbates EAE disease 
severity. Mice were treated with MB22-10 (closed circles) or control (open circles) mAb (250 µg, 
arrowheads) from day -7 (days -7, 0, 7, 14, 21), from day 7 (days 7, 14, 21), from day 14 (days 
14, 21), or from day 21, as indicated. Values represent mean (±SEM) EAE clinical scores from 
≥5 mice in each group, with similar results obtained in 2 independent experiments. Significant 
differences between MB22-10 and control mAb-treated groups are indicated; *p<0.05. (C) Treg 
cell deletion. Representative results demonstrate spleen CD4+CD25+FoxP3+ Treg cell 
frequencies within the indicated gates among total CD4+ T cells and Treg cell numbers in wild 
type mice 7 days after initial denileukin diftitox or PBS treatments. Denileukin diftitox was 
administrated 1, 3 or 6 days before analysis or 1, 4 and 7 days before analysis as indicated. Bar 
graphs indicate mean (±SEM) percentages and numbers of CD4+CD25+FoxP3+ Treg cells from 6 
mice in each group from two pooled independent experiments. Significant differences between 
denileukin diftitox or PBS treatment groups are indicated; *p<0.05, **, p<0.01. (D) Late Treg 
cell deletion exacerbates EAE disease severity. Mice were treated with denileukin diftitox 
(closed circles) or PBS (open circles) before (days 1, 4, 7, 10, 13, arrowheads) or after EAE 
onset (days 14, 17, 20, 23, 26, arrowheads). Values represent mean (±SEM) EAE clinical scores 
from ≥5 mice in each group, with similar results obtained in 2 independent experiments. 




Figure 4. Changes in B10 and Treg cell frequencies and numbers within tissues during the 
course of EAE. Mononuclear cells were isolated from (A) CNS tissue, (B) inguinal and axillary 
lymph nodes draining the site of MOG immunization, or (C) blood before, and 7, 14, 21 or 28 
days after MOG35-55 immunizations (left panels). Representative results demonstrate the 
frequencies of IL-10-producing cells after L+PIM stimulation for 5 h within the indicated gates 
among total CD19+ B cells, as well as CD4+CD25+FoxP3+ Treg cell frequencies among total 
CD4+ T cells. Bar graphs indicate mean (±SEM) frequencies and numbers of B cells that 
produced IL-10 or CD25+FoxP3+CD4+ Treg cells from 6 mice in each group from two pooled 
independent experiments. Horizontal dashed lines are provided for reference to naïve mice. (D) 
Treg cells dominate CNS tissues after EAE development. Bar graphs indicate mean (±SEM) 
percentages of IL-10+ B10 cells relative to total IL-10+ B10 cells plus Treg cells within various 
tissues. (A-D) Significant differences between means of naïve mice and mice with EAE are 
indicated; *p<0.05, **, p<0.01. Similar results were obtained in at least 2 independent 
experiments. 
 
Figure 5. The adoptive transfer of MOG35-55-sensitized B10 cells can reduce EAE disease 
severity in wild type mice. (A-B) Representative B10 cell purification results for adoptive 
transfer experiments. Purified spleen B cells from naïve mice or mice with EAE (day 28) were 
separated into CD1dhiCD5+CD19+ and CD1dloCD5-CD19+ B cell populations. The isolated cells 
were cultured with L+PIM for 5 h, or were cultured with agonistic CD40 mAb for 48 h with 
L+PIM added during the final 5 h of culture. B10 cell frequencies in the stimulated cell cultures 
were determined by immunofluorescence staining with flow cytometry analysis. (C) The 
adoptive transfer of purified spleen CD1dhiCD5+ B cells reduces EAE disease severity. Wild 
type recipient mice were given either PBS, CD1dhiCD5+ B cells, or CD1dloCD5- B cells from 
naïve wild type mice, mice with EAE (day 28), or IL-10-/- mice with EAE (day 28) 1 day before 
MOG35-55 immunizations or 7 or 14 days after MOG35-55 immunization as indicated (arrowheads). 
In some cases, the purified B cell populations were stimulated as indicated with agonistic CD40 
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mAb for 48 h, with LPS added during the final 5 h of culture to induce B10pro cell maturation 
and thereby expand B10 cell frequencies. Values represent means (±SEM) from ≥5 mice in each 
group, with similar results obtained in 2 independent experiments. Significant differences 
between the means of EAE clinical scores are indicated: *p<0.05 (black diamond versus white 
circle). 
 
Figure 6. Treg cell and leukocyte infiltration into the CNS following the adoptive transfer of 
B10 cells. Wild type recipient mice were given PBS, or either CD40/LPS-stimulated 
CD1dhiCD5+ or CD1dloCD5- B cells from mice with EAE (day 28) 1 day before MOG35-55 
immunizations as in figure 5C. (A) Mononuclear cells within CNS tissues or spleen 18 days after 
MOG35-55 immunizations. Bar graphs indicate mean (±SEM) numbers of CD4+ T cells or 
frequencies/numbers of CD4+CD25+FoxP3+ Treg cells among total CD4+ T cells (n≥5 mice per 
group). Significant differences between groups of mice receiving CD1dhiCD5+ B cells or PBS 
are indicated; **p<0.01. Similar results were obtained in at least 2 independent experiments. (B-
D) EAE histopathology following the adoptive transfer of B10 cells. Representative lumbar 
spinal cord sections were harvested 18 days after MOG35-55 immunizations (n≥5 mice per group) 
with (B) inflammation (H&E staining) and (C) demyelination (Luxol Fast Blue staining) 
demonstrated. Scale bar is 0.5 mm. B) Arrowheads indicate inflammatory foci. C) Yellow traced 
areas indicate demyelination. (D) Bar graphs indicate mean (±SEM) numbers of inflammatory 
foci and percentages of spinal cord sections that were demyelinated, with significant differences 
between groups of mice receiving CD1dhiCD5+ B cells or PBS indicated; **p<0.01. Similar 
results were obtained in at least 2 independent experiments. 
 
Figure 7. B10 cells alter T cell cytokine profiles, but not T cell proliferation. Purified splenic 
CD1dhiCD5+ or CD1dloCD5- B cells from mice with EAE (day 28) were stimulated with 
agonistic CD40 mAb for 48 h, with LPS added during the final 5 h of culture. (A) B10 cell 
effects on T cell proliferation. CFSE-labeled TCRMOG CD4+ T cells were cultured alone or with 
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CD40/LPS-stimulated CD1dhiCD5+ or CD1dloCD5- B cells in the presence of MOG35-55 (25 
µg/ml) for 72 h. After 72 h, the cultured cells were stained for CD4 and Thy1.1 expression and 
analyzed for CFSE dilution by flow cytometry. Representative frequencies of dividing CFSE-
labeled cells are shown (gated on CD4+Thy1.1+CFSE+ cells). Bar graphs (left) indicate CFSE 
geometric mean fluorescence of the entire histogram, which is inversely proportional to cell 
divisions. Bar graphs (right) indicate mean (±SEM) frequencies of dividing TCRMOG CD4+ T 
cells (CD1dhiCD5+ B cell group, closed bars; CD1dloCD5- B cell group, open bars) from 6 mice 
in each group from two pooled independent experiments. (B) B10 cells alter CD4+ T cell 
cytokine production. TCRMOG CD4+ T cells were cultured with CD40/LPS-stimulated 
CD1dhiCD5+ or CD1dloCD5- B cells from wild type or IL-10-/- mice with EAE (day 28) in the 
presence of MOG35-55 (25 µg/ml) for 72 h, with PMA, ionomycin, and BFA added during the 
final 5 h of culture. For negative controls, TCRMOG CD4+ T cells were cultured with CD40/LPS-
stimulated CD1dloCD5- B cells in the presence of MOG35-55 (25 µg/ml) for 72 h, with BFA alone 
(without PMA/ionomycin) added during the final 5 h of culture. Cytokine production by 
TCRMOG CD4+ T cells was determined by intracellular cytokine staining with flow cytometry 
analysis. Numbers indicate percentages of T cells within the indicated gates among total CD4+ T 
cells. Bar graphs indicate mean (±SEM) percentages of cytokine producing CD4+ T cells from 6 
mice in each group from two pooled independent experiments. (C) Representative IL-10R 
expression (thick line) by splenic CD11c+ DCs, CD11bhi macrophages, CD19+ B cells, CD4+ T 
cells, and CD8+ T cells from wild type mice before or 7 days after MOG35-55 immunization. Gray 
histograms represent isotype-matched control mAb staining. Bar graphs indicate average mean 
linear fluorescence intensities (±SEM) of IL-10R expression by each cell type from 6 mice in 
each group from two pooled independent experiments. (D) B10 cells inhibit the ability of DCs to 
activate CD4+ T cells. Splenic CD1dhiCD5+ or CD1dloCD5- B cells from mice with EAE (day 
28) were purified by cell sorting, and cultured with agonistic CD40 mAb for 48 h, with LPS 
added during the final 5 h of culture. Purified splenic DCs from mice with EAE (day 10) were 
cultured alone or with CD40/LPS-stimulated CD1dhiCD5+ or CD1dloCD5- B cells in the presence 
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of MOG35-55 (25 µg/ml) for 72 h. DCs purified from the B cell co-cultures were then cultured 
with TCRMOG CD4+ T cells for 72 h, or the T cells were cultured alone, with CD4 and Thy1.1 
expression and CFSE dilution analyzed by flow cytometry. Mean frequencies of dividing CFSE-
labeled CD4+Thy1.1+CFSE+ cells are indicated (±SEM) in each histogram from 6 mice in each 
group from two pooled independent experiments. Bar graphs indicate CFSE geometric mean 
fluorescence of the entire histogram, which is inversely proportional to cell divisions. Significant 
differences between groups indicated; *p<0.05. 
 







